MBRX logo

MBRX
Moleculin Biotech Inc

22,144
Mkt Cap
$12.49M
Volume
206,904.00
52W High
$24.00
52W Low
$1.79
PE Ratio
-0.09
MBRX Fundamentals
Price
$2.38
Prev Close
$2.39
Open
$2.45
50D MA
$2.37
Beta
0.93
Avg. Volume
110,080.82
EPS (Annual)
-$28.42
P/B
0.84
Rev/Employee
$0.00
$4.60
Loading...
Loading...
News
all
press releases
Scalable Biotech Manufacturing Unlocks a $14B Market
Scalable Biotech Manufacturing Unlocks a $14B Market Scalable Biotech Manufacturing Unlocks a $14B Market PR Newswire VANCOUVER, BC, March 27, 2026 Issued on behalf of Ava Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary The global cell therapy manufacturing...
News Placeholder
More News
News Placeholder
Why Did MBRX Stock Climb 14% Today?
Moleculin Biotech said on Wednesday that it is on track to treat the 45th patient with Annamycin as part of its Miracle study.
News Placeholder
Why Did MBRX Stock Plummet Over 25% Today?
Moleculin Biotech will implement a 1-for-25 reverse stock split of its common stock, effective December 1.
News Placeholder
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...
News Placeholder
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
News Placeholder
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup
The trial, which will involve sites in the U.S., Europe, and the Middle East, aims to combine Phase 2B and Phase 3 data for efficacy evaluation of the Miracle trial of Annamycin for relapsed or refractory acute myeloid leukemia.
News Placeholder
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week
New trial data, a reverse split, and financing moves triggered a spike in retail chatter for these biotech stocks in the week ending Feb. 28, 2025.
News Placeholder
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available